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Background: Women die of stroke more often than men. After menopause, the incidence of ischemic stroke
increases rapidly. Elevated fibrinogen levels and smoking have been associated with an increased risk of stroke. In
gene-cluster haplotype analyses, the beta-fibrinogen (FGB) promoter −455 G/A polymorphic locus was most
strongly associated with elevated plasma fibrinogen levels. We investigated whether the FGB −455 G/A polymorphism
and smoking might interact with sex on longterm survival of acute stroke sufferers.
Methods: The Stroke Aging Memory (SAM) cohort comprising 486 consecutive stroke patients (55–85 years, 246 men,
240 women) subjected to clinical and MRI examination was followed over 12.5 years. During this period 347 (71.4%)
patients died. The genotypes of the FGB −455 G/A polymorphism were determined by PCR.
Results: The FGB −455 G/A polymorphism genotype distributions were 64.7%, 32.1%, and 3.2% for GG, GA, and AA,
respectively. During the follow-up, the FGB −455 A + genotype did not associate with survival, nor was there any
genotype-by-smoking interaction on poor outcome in the total study population. However, women aged 55–71 years
who carried the FGB −455 A-allele showed worse survival regardless of smoking status compared to non-smoking FGB
−455 GG homozygotes (non-smokers, crude HR = 5.21, 95% CI: 1.38-19.7; smokers, crude HR = 7.03, 95% CI: 1.81-27.3).
This association persisted in adjusted analyses. No such association was observed for women in the oldest age-group,
nor among men.
Conclusion: The A + genotype of the FGB −455 G/A polymorphism associated with poor survival among 55–71 years
old Caucasian women in the Finnish stroke cohort.
Keywords: Adult, Cohort study, Cerebral infarction, Stroke, Risk factors, Genetic and inherited disorders, Genetics,
Genetic polymorphisms, Fibrinogen, Haematological disordersBackground
Cardiovascular and cerebrovascular diseases are major
causes of death in industrialized countries, and stroke is
the leading cause of adult disability in the developed world
[1,2]. While combined death rates and hospitalization
periods of cardiovascular diseases due to myocardial* Correspondence: timo.erkinjuntti@hus.fi
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article, unless otherwise stated.infarction have decreased greatly, the numbers related to
stroke have decreased only slightly. In addition to family
history and lifestyle factors, gene-environment interac-
tions seem to determine the development and manifest-
ation of cardio- and cerebrovascular diseases through
inflammatory and prothrombotic processes [3-7].
Despite a lower incidence of stroke over one’s lifetime,
women are twice as likely to die from stroke as men and
during menopause the incidence of ischemic stroke in-
creases rapidly [8-10]. Postmenopausal women suffer
more severe and fatal strokes indicating the presence ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Possible approaches to the search for genetic factors of
stroke are genome-wide association studies (GWAS) and
candidate gene studies. While GWAS have uncovered
numerous associations with metabolic endpoints, it has
been more challenging to discover associations with
complex diseases in spite of the formation of large con-
sortia [12]. An alternative to GWAS is the investigation
of candidate genes based on knowledge of risk factors or
the pathophysiology of the disease.
Fibrinogen is a dimeric 340 kDa acute phase glycopro-
tein synthesized by the liver. It consists of three polypep-
tides Aα, Bβ and γ coded by the alpha (FGA), beta
(FGB) and gamma (FGG) genes, respectively [13]. Fi-
brinogen is an important component of the coagulation
cascade and a major determinant of blood viscosity and
platelet aggregation. It modulates endothelial function
and promotes smooth muscle cell proliferation and mi-
gration [4,7]. Smoking increases blood fibrinogen con-
centration and is a significant risk factor for stroke
[14-16]. Recently, obesity has been associated with ele-
vated fibrinogen and CRP levels [17].
In the SAM cohort, we have previously found a
genotype-by-smoking interaction between the A-allele of
the FGB −455 G/A polymorphism and recurrent lacunar
infarcts, as well as an interaction between smoking and
the blood platelet fibrinogen receptor (GpIIb/IIIa) PlA2
allele as a risk factor for lacunar cerebral infarction
[18,19]. In haplotype analyses covering the entire FGB-
gene, the FGB −455 G/A polymorphism (rs1800790)
shows the strongest association with blood fibrinogen
levels, although a direct relationship with atherothrom-
botic disease is lacking [6,20-25].
The A + genotype of the FGB −455 G/A polymorph-
ism acts as an individual risk factor for coronary artery
disease (CAD), acute coronary syndromes (ACS), per-
ipheral arterial disease (PAD) and stroke [7,14,26-30]. In
the present study our hypothesis is that the FGB
−455 G/A polymorphism might interact with smoking
and interfere sex specific longterm survival after stroke.
Methods
Patients
The Helsinki Stroke Aging Memory (SAM) cohort
comprises of a consecutive series of all Finnish (Cau-
casian) patients with suspected stroke admitted to
Helsinki University Central Hospital (n = 1622) be-
tween the 1st of December 1993 and the 30th of March
1995. A total of 486 (246 men, 240 women) living pa-
tients aged 55 to 85 years (mean age 71.3 years) were
recruited for the study 3 months after experiencing an
ischemic stroke - more detailed descriptions of the
study series and methods have been described else-
where [17,18,31,32].General clinical assessment
A structured medical and neurological history was re-
corded during hospitalization for the index stroke that
was also the time point of laboratory sample collection
and blood pressure measurements in addition to MRI
investigation. History of cardiac risk factors (myocardial
infarction, cardiac failure, atrial fibrillation), arterial
hypertension, peripheral arterial disease, and diabetes
was investigated by reviewing all available hospital
charts, in addition to a structured interview of the sub-
ject and a knowledgeable informant. Hypertension was
defined as blood pressure ≥160/95 mm Hg. Smoking
habit was scored as non-smokers or smokers, with non-
smokers only those who had never smoked. Diabetes
was defined as previously documented diagnosis, current
use of insulin or oral antidiabetic medication, or fasting
blood glucose >7.0 mmol/L. Laboratory analyses in-
cluded total and HDL cholesterol, triglycerides, and fast-
ing blood glucose. Total cholesterol was considered high
at >6.5 mmol/L. Carotid stenosis was defined as >50%
stenosis of vessel diameter. 383 patients (78.8%) of the
SAM cohort underwent a brain MRI investigation, and
371 patients had both MRI and genotype data. Infarct
subtype definitions for lacunar (LAI) and large-vessel in-
farcts (LVI) have been presented earlier [33]. There were
116 (23.8%) of patients with missing values in MRI,
cause of death, biochemical or genotype data. The final
follow-up study population did not differ in risk factor,
stroke type, demographic, or medical parameters from
the original cohort. The analyzed and excluded patients
did not differ in either vascular risk factors or stroke
type (Table 1). Data on survival were collected over a
12.5 year period during which 347 (71.4%) of the pa-
tients deceased. MRI, genotype and cause of death data
was available for 262 (53.9%) patients. The study was ap-
proved by the ethics committee of the Helsinki Univer-
sity Central Hospital, Helsinki, Finland. The study was
explained to the patients, and informed consent was
obtained.
DNA preparation
DNA was separated from frozen blood samples accord-
ing to standard procedures. The genotypes of the FGB
−455 G/A polymorphism were detected by polymerase
chain reaction (PCR) and restriction enzyme digestion,
followed by poly-acrylamide gel electrophoresis. Primer
sequences and the PCR protocol have been previously
described in detail [34].
Statistical analysis
Data was analysed using SPSS/WIN (version 20.0, SPSS
Inc.) software. The number of A/A homozygotes of the
FGB −455 G/A polymorphism was small among SAM
cohort patients and therefore A/A homozygotes and G/A
Table 1 Main characteristics of 371 patients in the SAM
cohort with survival and genotype data according to
-455G/A genotypes
Variable FGB −455 G/A genotype
G/G (n = 240) G/A + A/A (n = 131)
Age (mean, SD), y 71.1 (7.67) 71.0 (8.10)
Women, % 48.3 53.4
CRP >10 mg/L, % 18.3 16.7
Diabetes, % 23.8 21.4
Hypertension, % 47.1 50.4
Hypercholesterolemia, % 15.4 17.6
Mean fs-Chol (SD) 5.56 (1.14) 5.57 (1.23)
Mean fs-Chol-HDL (SD) 1.15 (0.34) 1.15 (0.34)
Hypertrigyceridemia, % 2.1 3.1
Smoking, % 48.5 53.8
Subtypes of ischemic stroke
Large artery, % 17.3 18.1
Cardioembolic, % 5.4 8.4
Lacunar, % 15.4 11.5
Other, % 62.1 61.8
MI, % 17.9 19.1
Arrhythmia, % 24.2 24.4
Carotid artery stenosis, % 12.5 10.7
Atrial fibrillation, % 17.2 20.6
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genotype variable of the of the FGB −455 G/A polymorph-
ism. The data was analysed as whole and in subgroups
that were formed using sex and the mean age (71 years) to
divide the data into age groups (55–71 and 72–85 years
old) in intention to study the sex and age dependence. To
study the association between risk factors including FGB
−455 G/A A + genotype and survival we first analysed the
data by Kaplan-Meier (log rank) survival analysis and
graphical approach was used in verification that the pro-
portional hazards assumption was met. Subsequently, the
Cox regression proportional hazards model was used to
study the association between FGB −455 G/A A + geno-
type and survival. First we obtained crude hazard ratios
(HRs) and confidence intervals (CIs) and then we used
multivariate Cox regression analysis in further statistical
testing of genotype-survival association with age, history
of previous arrhythmias, atrial fibrillation (AF), carotid
stenosis (CS), elevated CRP (>10 mg/l), diabetes, hyper-
cholesterolemia, hypertension, hypertriglyceridemia, his-
tory of myocardial infarction (MI), sex and smoking
pooled into forced and forward stepwise likelihood ratio
(LR) models. To further adjust the analyses we stratified
Cox regression models (forced and forward stepwise) with
each modifier (history of previous arrhythmias, AF, CS,elevated CRP (>10 mg/l), diabetes, hypercholesterolemia,
hypertension, hypertriglyceridemia, history of MI and
smoking) separately and used age and sex as confounders.
The data concerning the history of arrhythmias, AF, CS,
diabetes, hypertension, hypercholesterolemia and hypertri-
glyceridemia was missing in 118 (24.3%) of patients. Fur-
thermore, based on Little’s MCAR (missing completely at
random) test (p < 0.05) we concluded that the data was
not missing completely at random. Overall summary of
missing values showed that each case with missing values
had, on average, missing values on roughly 3.37 of the 10
variables suggesting that listwise deletion would lose much
of the information in the data. The data missingness pat-
tern was nonmonotone and the random number gener-
ator was used to simulate missing values for each
observation that were imputed with fully conditional spe-
cification (FCS) Markov Chain – Monte Carlo (MCMC)
method assuming multivariate normality and five imputa-
tions was suitable in graphic check for FCS convergence.
Then we analyzed the complete data with Cox regression
model to check differences in survival in total population
and in subgroups with pooled parameter estimates and we
also checked of the variation in the regression coefficient
estimates from imputation to imputation, and against the
original data. The results were not altered after imputa-
tions. Survival analyses for LAI or LVI subgroups, stroke
types (TOAST) and specific causes of death were also
completed. According to power calculations our study
population has the power to show hazard ratios >2.5 to be
statistically significant with 0.80 probability (power) when
the Type I error probability is 0.05 [35].
Results
Prevalence of FGB −455 G/A alleles
There were 371 patients with the FGB −455 G/A poly-
morphism genotype and clinical data available. The
study population comprised 50.7% (186) male patients.
The mean age was 71.0 years (SD ± 7.81) and the data
was normally distributed. There were 186 smokers
(50.1%) in the study population (84.9% men and 15.1%
women). Allele distributions were in Hardy-Weinberg
equilibrium (p = 0.74). Genotype distributions were
64.7% for GG, 32.1% for GA, and 3.2% for AA. These
frequencies closely correspond to the population fre-
quencies among whites; in the ECTIM study, the allele
frequencies were 65.9%, 29.1%, and 4.9%, respectively
[27]. The main demographic parameters are represented
in Table 1.
Causes of death
Of the series 262 (70.6%) patients with genotype and
MRI data died during an average of 12.5 years of follow-
up. Cardiovascular diseases were the cause of death in
the majority of cases (33.6% of men and 30.5% of
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ences between sexes in the causes of death; 37.7% of
women and 29.5% of men had brain related causes of
death and 34.6% of women and 27.3% of men had ische-
mic brain insults. However, 72–85 years old men had
more often brain related (35.4% vs. 20.8%, p = 0.007)
and ischemic brain insults (32.9% vs. 18.9%, p = 0.01) as
cause of death compared to 55–71 years old men
(Table 2). In addition, ischemic brain insults and cardio-
vascular diseases were more often the cause of death
among women aged 72–85 years compared to younger
age group (36.7% vs. 23.8%, p = 0.06; 33.9% vs. 19.0, p =
0.04, respectively). Furthermore, cerebral bleeding was
the cause of death more often among 55–71 years old
women compared to older age group (14.3% vs. 2.8%, p <
0.001) (Table 2).
Long-term survival
As expected, age was associated (p < 0.001) with survival
in Kaplan-Meier log rank analyses. In the multivariate
Cox regression model, age (HR = 1.08, 95% CI: 1.06-
2.00, p = 0.005) and diabetes (HR = 1.39, 95% CI: 1.05-
1.83, p = 0.03) associated significantly with poor survival.
However, significant association between diabetes and risk
of cardiac death (HR = 1.59, 95% CI: 0.97-2.59) was not
observed in multivariate Cox regression analysis. Smoking
had no statistically significant (p = 0.06) effect on survival
in the Kaplan-Meier log rank analysis that was also ob-
served in the multivariate Cox Regression model (HR =
1.26, 95% CI: 0.97-1.65) and it was not dependent on sex.
In contrast, hypercholesterolemia or elevated cholesterol
levels known to increase risk for further cardiovascular
events, but paradoxically associates with lower mortality
in old age had a positive (HR = 0.65, 95% CI: 0.43-0.99,Table 2 Causes of death according to age group (55–71 and 72




n 55-71 yrs 72-85 yrs
n = 74 n = 188
(28.2%) (71.8%)
Brain related 262 18 (24.3) 70 (37.2)
Ischemic 262 15 (20.3) 66 (35.1)
Bleeding 262 4 (5.4) 6 (3.2)
Dementia 262 3 (4.1) 5 (2.7)
Cardiac 262 25 (33.8) 55 (29.3)
Cancer 262 15 (20.3) 23 (12.2)
Infection 262 1 (1.4) 10 (5.3)
Trauma 262 4 (5.4) 6 (3.2)
Other 262 10 (13.5) 22 (11.7)
All figures in parentheses are percentages.
From the categories ‘all’ and men, 1 case was excluded as cause of death could notp = 0.05) impact on longterm post stroke survival in
Cox regression model [36].
We did not observe statistically significant (p-values
>0.05) association between the FGB −455 G/A A-allele
and poor survival in the total study population, nor in
men or women separately (Kaplan-Meier log rank and
Cox regression model). In addition, genotype-by-smoking
interaction on survival in the total study population was
not observed in the Kaplan-Meier log rank analysis that
remained insignificant in Cox Regression model (Table 3).
However, patients with FGB −455 G/A A + genotype of
the younger age group (55–71 years old) had worse sur-
vival (non-smoker HR = 2.37, 95% CI: 1.24-4.41; smoker
HR = 2.33, 95% CI: 1.20-4.52) despite of smoking status
suggesting an association between the carrier status of the
FGB −455 G/A A-allele and elevated risk for death
(Table 3). In subgroup analysis we detected a significant
association between the A + genotype of the FGB −455 G/
A polymorphism and worse post stroke survival in 55–71
year old women in Kaplan-Meier (p = 0.013) log rank ana-
lysis and multivariate Cox Regression forced model (non-
smoker, crude HR = 5.21, 95% CI: 1.38-19.7, p = 0.015;
smoker, crude HR = 7.03, 95% CI: 1.81-27.3, p = 0.005)
(Figure 1 and Table 3). When history of arrhythmias, AF,
CS, CRP, diabetes, hypercholesterolemia, hypertension,
hypertriglyceridemia, and history of MI were forced into
Cox regression model, the association between FGB −455
A-allele and worse survival persisted, however wider CIs
were observed reflecting smaller sample size (non-smoker
HR = 41.0, 95% CI: 3.23-520, p = 0.004; smoker HR =
37.2, 95% CI: 2.50-548, p = 0.009). Similar results was ob-
tained in Cox regression forward stepwise LR (likelihood
ratio) model (non-smoker HR = 26.9, 95% CI: 2.58-279,
p = 0.006; smoker HR = 36.1, 95% CI: 3.42-381, p = 0.003)–85 years) and sex during longterm post stroke follow-up
Men Men Women Women
55-71 yrs 72-85 yrs 55-71 yrs 72-85 yrs
n = 53 n = 79 n = 21 n = 109
(40.2%) (59.8%) (16.2%) (83.8%)
11 (20.8) 28 (35.4) 7 (33.3) 42 (38.5)
10 (18.9) 26 (32.9) 5 (23.8) 40 (36.7)
1 (1.9) 3 (3.8) 3 (14.3) 3 (2.8)
1 (1.9) 4 (5.1) 2 (9.5%) 1 (0.9)
21 (39.6) 18 (22.8) 4 (19.0) 37 (33.9)
9 (17.0) 14 (17.7) 6 (28.6) 9 (8.3)
1 (1.9) 5 (6.3) 0 (0.0) 5 (4.6)
4 (7.5) 3 (3.8) 0 (0.0) 3 (2.3)
7 (5.3) 10 (12.7) 3 (14.3) 12 (11.0)
be specified.
Table 3 Cox regression analysis of the association of the FGB −455 G/A genotype-by-smoking interaction term with





All Age group Age group Men Women Men Women
HR 95% CI 55–71 years 72–85 years (55–71 years) (55–71 years) (72–85 years) (72–85 years)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
All n 369 165 204 104 61 80 124
Event n 262 90 172 64 25 69 104
GG nonsmoker Ref. Ref. Ref. Ref. Ref. Ref. Ref.
GG smoker 1.03 (0.71-1.49) 1.35 (0.65-2.80) 0.91 (0.59-1.41) 1.07 (0.39-2.94) 3.46 (0.89-13.4) 1.38 (0.45-4.31) 0.83 (0.52-1.34)
GA/AA nonsmoker 1.34 (0.99-1.81) 2.00 (1.13-3.54) 1.27 (0.88-1.81) 1.21 (0.64-2.30) 5.21 (1.38-19.7) 1.62 (0.84-3.12) 1.17 (0.70-1.95)
GA/AA smoker 1.18 (0.83-1.67) 2.03 (1.11-3.70) 1.11 (0.70-1.75) 1.10 (0.56-2.17) 7.03 (1.81-27.3) 1.57 (0.74-3.30) 0.93 (0.47-1.84)
Data shown for the total population and for, subgroups based on age (55–71 and 72–85 years old) and further divided by sex.
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each modifier showed that elevated CRP strengthened the
effect of smoking and FGB −455 G/A polymorphism on
worse survival in women aged 55–71 years (GG smokers,
adjusted HR: 9.83, 95% CI 1.20-80.1; GA/AA non-smokers,
adjusted HR: 15.4, 95% CI 1.91-124; GA/AA smokers, ad-
justed HR: 24.9, 95% CI 3.00-206), however the number of
patients decreased considerably in this model (Figure 2).
This association was not seen in 72–85 years old women
or in men. In addition, we found no genotype-by-smoking
interaction with specified cause of death in any age group
of men or women.
Discussion
The A + genotype of the FGB −455 G/A polymorphism
was associated with poor post stroke survival among
55–71 years old postmenopausal women of the Stroke
Aging Memory (SAM) study cohort, representing a con-
secutive series of all Finnish (Caucasian) patients with
suspected stroke admitted to Helsinki University Central
Hospital during 16 months in 1993–1995. This associ-
ation was not observed in older women of the cohort or
among men.
In our study, the significant association between FGB
−455 G/A polymorphism and survival in total study
population was not observed. Pruissen et al. previously
studied the impact of FGB −455 G/A polymorphism and
other prothrombotic polymorphisms on composite out-
come events after cerebral ischemia of arterial origin
[37]. They found that FGB −455 G/A polymorphism did
not associate with survival that is in line with our results
when the whole series was studied without sex or age
dependences. The lack of significant association between
the A + genotype of the FGB −455 G/A polymorphism
and poor survival among older patients (72–85 years)
may be explained by the burden of other illnesses and
old age predisposing to poor outcome. However, our
finding on the association of FGB −455 G/A A-allele
with poor survival is restricted only to postmenopausalwomen of age 55 to 71 years for we had no premeno-
pausal women included into the SAM cohort. In addition,
we found that 34.6% of women and 27.3% of men had is-
chemic brain insults as the cause of death that supports
the concept that women are at greater risk of stroke after
menopause (Table 2). However, we did not observe any
genotype-by-smoking interaction with causes of death, al-
though smoking is known to increase fibrinogen levels.
During menopause, the protective effect of estrogen
against stroke and cardiovascular diseases reduces and
hormone replacement therapy (HRT) used to treat the
symptoms of menopause acts as a risk factor for stroke
[38-40]. Based on the data of The Finnish National
Health Institute, 32.0% of women aged 55–70 years and
11.0% of women aged 71–85 years used HRT during the
year 1996. Furthermore, 40.9% of women aged 55–64
years used HRT in Finland during the year 1999 [41].
The exact statistics concerning HRT use in the Helsinki
region during the early 1990’s could not be obtained as
national computer-based databases of pharmaceutical
store sales were gradually taken into use in Finland only
in the late 1990’s. As HRT is exclusively used in the
group of 55–70 year old women, in contrast to those at
the age of 71–85 we may speculate that our results
might be partly explained by a synergy between the FGB
−455 A + genotype, smoking and HRT. On the contrary,
transdermal estradiol therapy may have antiatherosclero-
tic effects in postmenopausal women by improving vas-
cular atherosclerosis [42]. Matsui S et al. have found that
HRT regimen using oral ultra-low-dose estradiol and
dydrogesterone has an improving effect on arterial stiff-
ness and insulin resistance in 28 postmenopausal women
[43]. As we do not have data on medication history that
is an important limitation of our study, the potential
effect of HRT on stroke risk or survival could not be
evaluated. Furthermore, HRT may act as a strong con-
founding factor and have an impact on the results.
The SAM cohort with study subpopulations are lim-
ited in size and the main finding of positive association
Men (55-71 years) Men (72-85 years)
Women (55-71 years) Women (72-85 years)
A B
C D
Figure 1 The effect of FGB -455G/A genotype-by-smoking interaction on overall post stroke survival (all cause death endpoint) in the
SAM cohort. Data shown on men (A: 55–71, and B: 72–85 years old); and women (C: 55–71, and D: 72–85 years old). Survival curves were
obtained by Kaplan-Meyer log rank analysis that showed poorer longterm survival in the 55–71 year old women who carried the FBG -455G/A
A-allele. This association was not dependent on smoking status in Cox regression forced model (non-smokers crude HR: 5.21, 95% CI 1.38-19.7;
smokers crude HR: 7.03, 95% CI 1.81-27.3). There were no significant associations with Kaplan-Meyer (log rank) or Cox regression analysis between
interaction terms and survival among men in both age groups or among older women (72–85 years).
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a subgroup of only 21 women aged 55–71 years old that
complicates the interpretation of the results. However,
this association without the smoking status dependence
was already observed in 55–71 years old patients of the
SAM cohort (Table 3). In addition, the SAM cohort is
too small to allow the detailed analysis of all fibrinogen
haplotypes and their impact on survival. One limitation
in our study is that the blood or plasma fibrinogen levelswere not determined. However the A-allele of the FGB
−455 G/A polymorphism has been shown to associate
with elevated fibrinogen levels and possess functional
properties [44].
Overweight/obese women without clustering of car-
diometabolic risk factors possess abnormal levels of
inflammatory markers including CRP and fibrinogen
suggesting that obesity represents a chronic inflamma-
tory state [17]. We could not assess the effect of obesity
CRP ADJUSTED SURVIVAL MODEL
Figure 2 The effect of FGB -455G/A genotype-by-smoking interaction adjusted for elevated CRP on overall post stroke survival (all
cause death endpoint) in the 55–71 year old women of the SAM cohort. Survival curves were obtained by Kaplan-Meyer log rank analysis
showed poorer longterm survival in the 55–71 year old women who smoked (p = 0.002). Hazard ratios and 95% confidence intervals were
obtained by Cox regression forced model adjusted for elevated CRP and the progressive effect of smoking and FGB −455 G/A polymorphism on
worse survival was observed ( GG smokers, adjusted HR: 9.83, 95% CI 1.20-80.1; GA/AA non-smokers, adjusted HR: 15.4, 95% CI 1.91-124; GA/AA
smokers, adjusted HR: 24.9, 95% CI 3.00-206).
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(>10 mg/L) value as a marker of inflammation caused a
significant increase in the point HR estimates addressing
the significant association of FGB −455 G/A A + geno-
type towards poor survival. However, the CIs widened
substantially that reflects the small number of patients
in this subgroup analysis (Figure 2). Therefore the inter-
action between FGB −455 G/A polymorphism and ele-
vated CRP remains unclear. In recent study of Ock SY
et al. the elevated plasma CRP concentration were dis-
cussed to be a reliable surrogate marker for predicting
carotid atherosclerosis severity in patients with AF, and
that CRP concentration may be related to an increased
risk of ischemic stroke [45]. In addition, CRP activity has
been positively correlated with plaque instability as well
as intima to media wall thickness of coronary arteries
and the common carotid artery [46,47]. Concerning
these, ischemic stroke is a complex trait with polygenic
and multifactorial inheritance with environmental trig-
gers [48,49]. Gene-environment-life style interactions in-
fluence the risk for stroke in an individual, and based
on our findings these may modify the survival from
stroke.
Misclassification of the exposure is unlikely since med-
ical history and risk factor data were derived from ad-
ministrative hospital data and genotyping was made in
the accredited laboratory. The stroke diagnosis and clas-
sification were based on MRI and patients were assessedby a senior neurologist that diminishes misclassification
of the outcome. In addition, the possibility of a selection
bias may underestimate the proportion of women who
died before hospital assessment at 3 months. Further-
more, the initiation of antithrombotic, antihypertensive
and lipid treatments poststroke may attenuate the effect
of genetic factors on survival. Limitations of the cohort
are also discussed in previous publication by Oksala N
et al. [19].
Conclusions
Taking in account the limitations of the present study,
our study highlights the contribution of the A + geno-
type of the FGB −455 G/A polymorphism towards poor
poststroke survival among 55–71 years old Caucasian
women even after adjustment for arrhythmias, AF, CS,
CRP, hypercholesterolemia, hypertension, hypertriglyc-
eridemia, and history of MI with age and sex as con-
founding factors. This association was not observed in
older women or among men. The SAM cohort does
not comprise stroke patients under 55 years old and the
association of FGB −455 G/A polymorphism with poor
survival could not be assessed in premenopausal
women. Furthermore, we found a substantial interaction
in the adjusted risk of death attributable to FGB
−455 G/A A + genotype and elevated CRP that warrants
the further investigation of possible gene-environment-
life-style interactions.
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